-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Kraig Biocraft Laboratories Enters Next Phase of Business Plan, Signs Deal with Contract Manufacturer to Produce Metric Tons of Recombinant Spider Silk
Kraig Biocraft Laboratories Enters Next Phase of Business Plan, Signs Deal with Contract Manufacturer to Produce Metric Tons of Recombinant Spider Silk
ANN ARBOR, Mich., July 18, 2022 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), the biotechnology company focused on the development and commercialization of spider silk, announces the signing of its first 3rd party production contract for large scale manufacturing of the Company's recombinant spider silk. The Company expects to immediately begin operations with this contractor to produce hundreds of kilograms of spider silk per month and to achieve production levels reaching multiple metric tons of spider silk per month as early as the first quarter of 2023. The contractor is in possession of the Company's specialized eggs and anticipates a 90-day ramp-up for the first deliveries under the contract.
Pilot testing with this contractor during the first two quarters of 2022 demonstrated the capacity and expertise of this manufacturer to operate at a large scale and with excellent quality.
Under the contract terms, Kraig Labs will become a minority owner of the silk producer. Kraig Labs will have complete access to the manufacturer's financial records and an onsite presence to ensure the proper handling and security of the Company's propriety spider silk technology.
"Our business model was designed to leverage the existing silk production infrastructure. The signing of this agreement rapidly expands our access into that production network and brings us to the next critical stage in our business plan," said Company COO Jon Rice. "Working with this contract manufacturer, we will soon be ready to deliver metric tons of eco-responsible and cost-effective spider silk to the consumer markets."
In the coming days, the Company plans to release the first in a series of behind-the-scenes videos looking into its operations in Vietnam and the commercialization of its spider silk materials.
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to .
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com
ANN ARBOR, Mich., July 18, 2022 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), the biotechnology company focused on the development and commercialization of spider silk, announces the signing of its first 3rd party production contract for large scale manufacturing of the Company's recombinant spider silk. The Company expects to immediately begin operations with this contractor to produce hundreds of kilograms of spider silk per month and to achieve production levels reaching multiple metric tons of spider silk per month as early as the first quarter of 2023. The contractor is in possession of the Company's specialized eggs and anticipates a 90-day ramp-up for the first deliveries under the contract.
密歇根州安阿伯,2022年7月18日(Global Newswire)--专注于蜘蛛丝开发和商业化的生物技术公司克莱格生物工艺实验室公司(OTCQB:KBLB)宣布,其首批3家研发承揽甲方生产规模化生产本公司的重组蜘蛛丝。该公司预计将立即与该承包商开始运营,每月生产数百公斤蜘蛛丝,并最早在2023年第一季度达到每月数吨蜘蛛丝的生产水平。承包商拥有该公司的专用鸡蛋,并预计合同规定的第一批交付将在90天内完成。
Pilot testing with this contractor during the first two quarters of 2022 demonstrated the capacity and expertise of this manufacturer to operate at a large scale and with excellent quality.
在2022年前两个季度与该承包商进行的试点测试表明,该制造商具有大规模和高质量运营的能力和专业知识。
Under the contract terms, Kraig Labs will become a minority owner of the silk producer. Kraig Labs will have complete access to the manufacturer's financial records and an onsite presence to ensure the proper handling and security of the Company's propriety spider silk technology.
根据合同条款,克莱格实验室将成为这家丝绸生产商的少数股权所有者。Kraig实验室将完全访问制造商的财务记录和现场存在,以确保公司适当的蜘蛛丝技术的适当处理和安全。
"Our business model was designed to leverage the existing silk production infrastructure. The signing of this agreement rapidly expands our access into that production network and brings us to the next critical stage in our business plan," said Company COO Jon Rice. "Working with this contract manufacturer, we will soon be ready to deliver metric tons of eco-responsible and cost-effective spider silk to the consumer markets."
公司首席运营官乔恩·赖斯表示:“我们的业务模式旨在利用现有的丝绸生产基础设施。这项协议的签署迅速扩大了我们进入该生产网络的渠道,并将我们带到了我们业务计划的下一个关键阶段。”与这家合同制造商合作,我们很快就能准备好向消费市场供应公吨环保且具有成本效益的蜘蛛丝。“
In the coming days, the Company plans to release the first in a series of behind-the-scenes videos looking into its operations in Vietnam and the commercialization of its spider silk materials.
在接下来的几天里,该公司计划发布一系列幕后视频中的第一个,这些视频考察了该公司在越南的业务,以及其蜘蛛丝材料的商业化情况。
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to .
要查看Kraig Labs的最新新闻和/或注册公司提醒,请访问。
About Kraig Biocraft Laboratories, Inc.
关于克莱格生物工艺实验室公司
Kraig Biocraft Laboratories, Inc. (), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.
Kraig Biocraft实验室公司()是一家全面报道生物技术的公司,是一家基于基因工程蜘蛛丝的纤维技术的开发商。
Cautionary Statement Regarding Forward Looking Information
关于前瞻性信息的警示声明
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
本新闻稿中除历史事实外有关公司未来和预期的陈述均为“前瞻性陈述”。这些陈述是根据管理层目前的看法和假设作出的。因此,不能保证管理层的期望一定会实现。这些前瞻性陈述通常可以通过“相信”、“计划”、“预期”、“预期”、“预见”、“估计”、“希望”、“如果”、“发展”、“研究”、“研究”、“试点”、“潜在”、“可能”或其他类似重要的词语或短语来识别。前瞻性陈述包括对公司业务战略、前景、目标、计划、意图和目标的描述。所有这些前瞻性陈述都会受到某些风险和不确定因素的影响,这些风险和不确定性可能会导致实际结果与前瞻性陈述中的结果大相径庭。本新闻稿不构成出售要约或征求购买任何证券的要约。
Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com
本·汉塞尔,Hansel Capital,LLC
(720) 288-8495
邮箱:ir@kraigLab.com
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧